Physician profile
Aileen A Smith
NPI 1366016040
$1,228.38
in general payments reported to CMS, 2019-2025
18 companies · $688 in 2025
The $688 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.54 · 2022: $73.74 · 2023: $115 · 2024: $322 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $259.63 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $227.95 | 2024-2025 | Tavneos, Repatha, Otezla |
| Corcept Therapeutics | $136.78 | 2024-2025 | Korlym |
| Pfizer INC. | $98.78 | 2021-2024 | |
| Shield Therapeutics INC | $76.43 | 2024-2025 | |
| Medtronic, INC. | $62.86 | 2022-2025 | Minimed 780g |
| Glaxosmithkline, LLC. | $57.87 | 2023 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.59 | 2024-2025 | Jardiance |
| Madrigal Pharmaceuticals | $43.81 | 2024-2025 | Resmetirom, Rezdiffra |
| Insulet Corporation | $40.90 | 2024-2025 | Omnipod |
| Echosens North America, INC. | $31.70 | 2025 | Fibroscan |
| Bayer Healthcare Pharmaceuticals INC. | $30.50 | 2025 | |
| Abbvie INC. | $28.76 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.76 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $17.47 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $15.75 | 2022 | |
| Sumitomo Pharma America, INC. | $15.36 | 2025 | Gemtesa |
| Tandem Diabetes Care, INC. | $14.48 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aileen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.